Literature DB >> 18346553

Noncompliance with the world health organization-multidrug therapy among leprosy patients in Cebu, Philippines: its causes and implications on the leprosy control program.

Elsie R Honrado1, Veronica Tallo, Angelita C Balis, Gertrude P Chan, Sang Nae Cho.   

Abstract

The success of current World Health Organization (WHO) key strategy for leprosy elimination (ie, multidrug therapy [MDT] regimen) depends largely on the efficiency of health care delivery services and patient compliance. A high rate of noncompliance with this regimen has serious implications for the leprosy control program because it can set the stage for the emergence of drug resistance, eventually resulting in treatment failure and failure of the program. A community-based descriptive study using pretested interviews conducted in 12 leprosy endemic areas in Cebu, Philippines, showed that the noncompliance rate with the WHO-MDT regimen among 233 study subjects was 30%. The causes of noncompliance are drug-related, health care provider-triggered, or patient-inducted, or some combination of these. Recommendations on strategic interventions to obviate the cause for noncompliance are presented.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18346553     DOI: 10.1016/j.det.2007.11.007

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  13 in total

Review 1.  Advances and hurdles on the way toward a leprosy vaccine.

Authors:  Malcolm S Duthie; Thomas P Gillis; Steven G Reed
Journal:  Hum Vaccin       Date:  2011-11-01

2.  Specific IgG antibody responses may be used to monitor leprosy treatment efficacy and as recurrence prognostic markers.

Authors:  M S Duthie; M N Hay; E M Rada; J Convit; L Ito; L K M Oyafuso; M I P Manini; I M B Goulart; J Lobato; L R Goulart; D Carter; S G Reed
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-05       Impact factor: 3.267

3.  Medical rehabilitation of leprosy patients discharged home in abia and ebonyi States of Nigeria.

Authors:  Ezinne Ezinna Enwereji; Eke Reginald Ahuizi; Okereke Chukwunenye Iheanocho; Kelechi Okechukwu Enwereji
Journal:  Oman Med J       Date:  2011-11

Review 4.  Application of nanotechnologies for improved immune response against infectious diseases in the developing world.

Authors:  Michael Look; Arunima Bandyopadhyay; Jeremy S Blum; Tarek M Fahmy
Journal:  Adv Drug Deliv Rev       Date:  2009-11-14       Impact factor: 15.470

5.  Interruption and defaulting of multidrug therapy against leprosy: population-based study in Brazil's Savannah Region.

Authors:  Jorg Heukelbach; Olga André Chichava; Alexcian Rodrigues de Oliveira; Kathrin Häfner; Friederike Walther; Carlos Henrique Morais de Alencar; Alberto Novaes Ramos; Adriana Cavalcante Ferreira; Liana Ariza
Journal:  PLoS Negl Trop Dis       Date:  2011-05-03

6.  Understanding non-compliance with WHO-multidrug therapy among leprosy patients in Assam, India.

Authors:  Sumit Kar; Ranabir Pal; Dharamvir Ranajan Bharati
Journal:  J Neurosci Rural Pract       Date:  2010-01

7.  Leprosy treatment dropout: a systematic review.

Authors:  Régio José Santiago Girão; Nara Lívia Rezende Soares; Juliana Viana Pinheiro; Giuliano da Paz Oliveira; Sionara Melo Figueiredo de Carvalho; Luiz Carlos de Abreu; Vitor E Valenti; Fernando Luiz Affonso Fonseca
Journal:  Int Arch Med       Date:  2013-08-30

8.  WHO multidrug therapy for leprosy: epidemiology of default in treatment in Agra district, Uttar Pradesh, India.

Authors:  Anil Kumar; Anita Girdhar; Joy Kumar Chakma; Bhuwneswar Kumar Girdhar
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

Review 9.  Combination chemoprophylaxis and immunoprophylaxis in reducing the incidence of leprosy.

Authors:  Malcolm S Duthie; Marivic F Balagon
Journal:  Risk Manag Healthc Policy       Date:  2016-04-27

10.  Patterns and determinants of treatment completion and default among newly diagnosed multibacillary leprosy patients: A retrospective cohort study.

Authors:  Veincent Christian F Pepito; Arianna Maever L Amit; Rae Erica D Samontina; Sarah Jane A Abdon; David Norman L Fuentes; Ofelia P Saniel
Journal:  Heliyon       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.